How to buy AbbVie (ABBV) stocks

AbbVie is a drug manufacturers - general business based in the US. AbbVie shares (ABBV) are listed on the NYSE and all prices are listed in US Dollars.

Its last market close was $205.29 – a decrease of 2.25% over the previous week. AbbVie employs 55,000 staff and has a trailing 12-month revenue of around $56.3 billion.

Our top picks for where to buy AbbVie stock

Buy AbbVie stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

Finder Score for stock trading platforms

To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score the better the platform - simple.

Read the full methodology

Related: Compare the best stock trading platforms in Canada

AbbVie stock price (NYSE: ABBV)

Use our graph to track the performance of ABBV stocks over time.

AbbVie stocks at a glance

• Key figures

Information last updated 2025-03-28.

Latest market close	$205.29
52-week range	$149.56 - $218.66
50-day moving average more info button	$196.46
200-day moving average more info button	$186.69
Wall St. target price	$211.73
PE ratio more info button	84.1162
Dividend yield more info button	$6.29 (3.26%)
Earnings per share (TTM) more info button	$2.41

Is it a good time to buy AbbVie stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Dive deeper: Our picks for the best stocks to buy right now in Canada

Is AbbVie stock undervalued or overvalued?

Valuing AbbVie stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AbbVie's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

AbbVie's P/E ratio

AbbVie's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 84x. In other words, AbbVie shares trade at around 84x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the stock or simply that they're over-valued.

AbbVie's PEG ratio

AbbVie's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.4214. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into AbbVie's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

AbbVie's EBITDA

AbbVie's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $26.7 billion.

The EBITDA is a measure of a AbbVie's overall financial performance and is widely used to measure a its profitability.

AbbVie financials

Revenue TTM	$56.3 billion
Operating margin TTM	36.66%
Gross profit TTM	$39.6 billion
Return on assets TTM	8.49%
Return on equity TTM	62.29%
Profit margin	7.59%
Book value	$1.88
Market Capitalization more info button	$358.6 billion

TTM: trailing 12 months

AbbVie stock dividends

Dividend payout ratio: 63.04% of net profits

Recently AbbVie has paid out, on average, around 100% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), AbbVie shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In AbbVie's case, that would currently equate to about $6.29 per share.

AbbVie's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

AbbVie's most recent dividend payout was on 14 May 2025. The latest dividend was paid out to all shareholders who bought their stocks by 14 April 2025 (the "ex-dividend date").

AbbVie stock price volatility

Over the last 12 months, AbbVie's stocks have ranged in value from as little as $149.557 up to $218.66. A popular way to gauge a stock's volatility is its "beta."

Beta is a measure of a stocks volatility in relation to the market. The market (NYSE average) beta is 1, while AbbVie's is 0.598. This would suggest that AbbVie's stocks are less volatile than average (for this exchange).

AbbVie overview

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Related: New to stock trading? Compare brokers and get tips for investing.

Frequently asked questions

What percentage of AbbVie is owned by insiders or institutions?
Currently 0.106% of AbbVie stocks are held by insiders and 73.939% by institutions. How many people work for AbbVie?
Latest data suggests 55,000 work at AbbVie. When does the fiscal year end for AbbVie?
AbbVie's fiscal year ends in December. Where is AbbVie based?
AbbVie's address is: 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 What is AbbVie's ISIN number?
AbbVie's international securities identification number is: US00287Y1091 What is AbbVie's CUSIP number?
AbbVie's Committee on Uniform Securities Identification Procedures number is: 00287Y109

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.